N※N

Eidolon Diagnostics Secures $145 Million Series B Funding to Accelerate AI-Driven Cancer Detection

85

  //media-entertainment.news-articles.net/content/ .. ng-to-accelerate-ai-driven-cancer-detection.html
  Published in Media and Entertainment on Monday, December 8th 2025 at 1:59 GMT by The Jerusalem Post Blogs

• 🞛 This publication is a summary or evaluation of another publication
• 🞛 This publication contains editorial commentary or bias from the source

2025-12-08 244 x 207 / 11178 Bytes

2025-12-08 223 x 224 / 13156 Bytes

2025-12-08 224 x 224 / 7992 Bytes

2025-12-08 224 x 224 / 10654 Bytes

Israel’s Next‑Gen Diagnostic Startup Secures Break‑through Funding, Promises to Revolutionize Early‑Stage Disease Detection

In a headline‑making move that underscores Israel’s burgeoning reputation as a global technology hub, the AI‑driven diagnostics company Eidolon Diagnostics announced on The Jerusalem Post that it has closed a $145 million Series B funding round. The investment—led by the venture arm of the Israeli government’s Israel Innovation Authority (IIA), alongside international heavyweights such as Sequoia Capital, Baidu Ventures, and BenevolentAI—will accelerate the company’s efforts to bring its patented Deep‑Vision platform to commercial markets in the United States, Europe, and Asia.

From a Small Lab to a Global Player

Eidolon was founded in 2019 by Dr. Yael Cohen, a former researcher at the Weizmann Institute of Science, and Mikhael Tzach, a serial entrepreneur who previously scaled Mimosa Bio, a biotech company acquired by Bayer. The duo combined Cohen’s expertise in optical imaging and computational pathology with Tzach’s knack for building and scaling high‑growth startups.

“Early detection is the single most effective way to improve patient outcomes,” Cohen explains. “Our Deep‑Vision system can analyze a single biopsy slide in under ten minutes, producing a risk score that is 97 % accurate for detecting early‑stage cancers that are traditionally missed by conventional pathology.” The platform leverages deep convolutional neural networks (CNNs) trained on over 2.5 million annotated histopathology images sourced from the Human Cancer Atlas and the National Cancer Institute (NCI) datasets.

The company’s first product, Eidolon Path, was validated in a Phase II clinical trial with 1,200 patients across three Israeli hospitals. The trial demonstrated that the AI‑assisted diagnoses reduced diagnostic time by 45 % and increased the detection rate of early‑stage breast cancer by 15 % compared with standard pathology workflows. The results were published in Nature Medicine and have attracted significant attention from both clinicians and payers.

The Funding Landscape and Its Significance

The $145 million round marks a cumulative valuation of $1.2 billion for Eidolon, placing it among Israel’s most valuable biotech companies. The funding comes at a pivotal moment when Israel’s biotech sector is witnessing a surge in AI‑enabled diagnostics, as reported by TechCrunch and Bloomberg in the first half of 2024.

According to the Israel Innovation Authority (IIA), the country’s biotech and medical‑device ecosystems grew by 6 % annually between 2021 and 2023, fueled by increased government support and a talent pool that blends engineering and life‑science expertise. The IIA’s investment in Eidolon reflects its National Strategy for Digital Health, which aims to “bridge the gap between clinical data and actionable insights through AI.”

The involvement of international investors such as Sequoia Capital—known for backing DeepMind and Stripe—and Baidu Ventures, which has been expanding its footprint in global healthtech, signals a growing confidence in the commercial viability of Israeli AI diagnostics. Meanwhile, BenevolentAI, an AI‑driven drug‑discovery company, is expected to partner with Eidolon on future research into early detection biomarkers for neurodegenerative diseases.

A Path Toward Global Expansion

Eidolon’s leadership has outlined a three‑phase expansion strategy:

1. Regulatory Approval: The company will seek FDA clearance for Eidolon Path in the U.S., targeting a 510(k) pathway that could be expedited under the FDA’s Digital Health Innovation Action Plan. Simultaneously, it plans to secure CE Marking in the EU, with a focus on the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for faster market entry.

2. Integration into Hospital Workflows: By 2025, Eidolon aims to partner with over 200 hospitals worldwide, providing cloud‑based AI services that integrate with existing laboratory information systems (LIS). The company’s API-first architecture enables seamless plug‑and‑play with both legacy and modern pathology platforms.

3. Expansion of Diagnostic Scope: Beyond oncology, the company will leverage its AI engine to detect early‑stage inflammatory bowel disease (IBD), celiac disease, and viral infections. A collaboration with Mayo Clinic’s Translational Bioinformatics Lab is already underway to test the platform on a new dataset of gastrointestinal biopsies.

“We are thrilled to have the support of such distinguished investors,” says Tzach. “With this funding, we can accelerate our clinical validation, expand our global footprint, and ultimately save millions of lives by catching disease earlier.”

Broader Impact on the Israeli Ecosystem

Eidolon’s success is being heralded as a blueprint for start‑ups in Israel’s “Startup Nation”. Yossi Kessler, the IIA’s chief executive, remarked, “Eidolon demonstrates the power of cross‑disciplinary collaboration. The company is not only advancing technology but also building the talent pipeline that will sustain Israel’s position at the forefront of medical AI.”

The company has also announced plans to create over 120 new jobs across Israel, Singapore, and the U.S., including roles in data science, regulatory affairs, and medical device engineering. In partnership with the Technion – Israel Institute of Technology and the Tel Aviv University School of Medicine, Eidolon will host a summer internship program to train the next generation of data‑driven clinicians.

Take‑away for Investors and Patients Alike

Eidolon’s story illustrates a dual narrative that is becoming increasingly common in Israel’s high‑tech ecosystem: the commercial potential of AI fused with a human‑centric mission to improve health outcomes. For investors, the company offers a compelling mix of scalable technology, proven clinical efficacy, and a clear regulatory roadmap. For patients, the platform promises faster, more accurate diagnoses that can translate into earlier interventions and better survival rates.

As the world grapples with the ongoing challenges of early‑stage disease detection, Eidolon’s Deep‑Vision platform stands out as a technological beacon—one that not only leverages Israel’s robust tech talent but also aligns with global priorities around precision medicine. With the recent infusion of capital and the momentum from its successful trials, the company is poised to set a new standard for AI‑driven diagnostics on a global scale.